| 1<br>2<br>3  | Cervical Cancer Screening Outcomes for HIV-positive Women in the Lubombo<br>and Manzini regions of Eswatini – Prevalence and Predictors of a Positive<br>Visual Inspection with Acetic Acid (VIA) Screen  |
|--|---|
| 4<br>5<br>7<br>8<br>9<br>10<br>11<br>12<br>13<br>14  | Short title: Cervical Cancer Screening Outcomes for HIV-positive women in Eswatini<br>Rufaro Mapaona <sup>1</sup> , Victor Williams <sup>1, 2</sup> , Normusa Musarapasi <sup>1</sup> , Sharon Kibwana <sup>3</sup> , Thokozani<br>Maseko <sup>1</sup> , Rhinos Chekenyere <sup>1,</sup> , Sidumo Gumbo <sup>1</sup> , Phetsile Mdluli <sup>1</sup> , Hugben Byarugaba <sup>1</sup> ,<br>Dileepa Galagedera <sup>1</sup> , Arnold Mafukidze <sup>1</sup> , Alejandra de Mendoza <sup>4</sup> , Prajakta Adsul <sup>5</sup> , Pido<br>Bongomin <sup>1</sup> , Christopher Loffredo <sup>4</sup> , Xolisile Dlamini <sup>6</sup> , Deus Bazira <sup>3</sup> , Sylvia Ojoo <sup>3</sup> , Samson<br>Haumba <sup>1, 3</sup> |
| 15<br>16<br>17<br>18<br>19<br>20<br>21<br>22<br>23<br>24<br>25   | <ol> <li>Author Affiliations:</li> <li>Center for Global Health Practice and Impact, Georgetown University, Mbabane, Eswatini.</li> <li>Julius Global Health, Julius Center for Health Sciences and Primary Care, University<br/>Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands</li> <li>Center for Global Health Practice and Impact, Georgetown University Medical Center,<br/>Washington DC, USA</li> <li>Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, USA</li> <li>University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, USA</li> <li>Ministry of Health, Mbabane, Eswatini</li> </ol>  |
| 26<br>27<br>28<br>29<br>30<br>31<br>32<br>33<br>34<br>35<br>36<br>37<br>38<br>39<br>40<br>41<br>42<br>43 | <b>Corresponding Author</b><br>Name: Victor Williams<br>Email: vmw20@georgetown.edu   |

# 44 Abstract

This study aimed to describe the prevalence and predictors of a positive VIA (visual inspection 45 46 with acetic acid) cervical cancer screening test in women living with human immunodeficiency virus (HIV). We retrospectively analysed data from women aged ≥15 who accessed VIA 47 screening from health facilities in the Lubombo and Manzini regions of Eswatini. 48 49 Sociodemographic and clinical data from October 2020 to June 2023 were extracted from the 50 client management information system. VIA screening outcome was categorised into negative, positive, or suspicious. A logistic regression model estimated the adjusted odds ratio 51 52 (AOR) of the predictors of a positive VIA screen at p<0.05 with 95% confidence intervals. Of 53 23,657 participants, 60.8% (n=14,397) were from the Manzini region. The mean age was 33.3 years (standard deviation 7.0), and 33% (n=7,714) were first-time screens. The prevalence of 54 a positive VIA was 2.6% (95% CI: 2.2%, 3.0%): 2.8% (95% CI: 2.2%, 3.5%) in Lubombo and 2.4% 55 (95% CI: 2.0%, 2.9%) in Manzini (p=0.096). Screening at mission-owned (OR 1.40; p=0.001), 56 NGO-owned (OR 3.08; p<0.001) and industrial/workplace-owned health facilities (OR 2.37; 57 58 p=0.044) were associated with positive test results compared to government-owned health 59 facilities, and being within the 35–44 age group (OR 1.26; p=0.017) compared to 25-34 years age group was a positive predictor of a positive VIA screen. Negative predictors of positive 60 VIA test were: being on anti-retroviral therapy (ART) for 5-9 years (OR 0.76; p=0.004) and  $\geq$ 10 61 years (OR 0.66; p=0.002) compared to <5 years; and having an undetectable viral load (OR 62 0.39; p<0.001) compared to unsuppressed. Longer duration on ART and an undetectable viral 63 64 load reduced the odds, while middle-aged women and screening at non-public health facilities 65 increased the odds of a positive VIA screen.

- 66
- 67
- 68

# 69 Introduction

Cervical cancer continues to be a leading cause of morbidity and mortality for women, despite
being preventable by vaccination against the human papillomavirus (HPV) and curable if
detected and treated early. There were an estimated 604,000 new cervical cancer cases and
342,000 deaths worldwide in 2020, and it is the fourth most frequently diagnosed cancer in
women [1].

75

There are substantial inequalities in the global cervical cancer burden: incidence is three times higher in countries with lower levels of human development, and more than 90% of deaths occur in these countries. The highest regional incidence and mortality occurs in Sub-Saharan Africa, where age-standardised incidence rates in Eastern Africa (40.1), Southern Africa (36.4) and Middle Africa (31.6) [2] are far higher than the threshold of 4 per 100,000 established by the World Health Assembly's Global Strategy for cervical cancer elimination [1].

82

Most cervical cancer cases (99.7%) are caused by persistent HPV infection [3], which is more 83 84 prevalent in HIV-infected women [4]. The natural history of HPV infection has a slow, 10-15year progression to pre-cancer in immuno-competent people. In HIV-infected women, the 85 condition progresses more frequently and quickly [5]. Cervical cancer is classified as an AIDS-86 87 defining illness. It is associated with lower CD4 cell counts and a lack of anti-retroviral therapy 88 (ART) among women living with HIV [6]. Globally, approximately 1 in 20 cervical cancers is attributable to HIV. In sub-Saharan Africa, about 1 in 5 cervical cancers is due to HIV, which 89 90 threatens the gains that improving access to HIV care and treatment has made in prolonging the life expectancy of these women. However, it is essential to note that although cervical 91

pre-cancer among women living with HIV is common, those who receive regular cervical
screenings among this population have low incidence rates of invasive cervical cancer [7].

94

Disparities in cervical cancer incidence and mortality reflect unequal access to and coverage 95 96 of comprehensive prevention (including HPV vaccination), screening and treatment of pre-97 cancerous lesions, and diagnosis and treatment of invasive cancers. The availability of these 98 services is suboptimal in low- and middle-income countries. As of 2020, less than 30% of 99 lower-middle-income countries had introduced the HPV vaccine, compared to 85% in highincome countries. Still, in 2020, less than 35% of low-income countries had national cervical 100 101 cancer screening programs, and less than 30% reported the availability of pathology services, 102 cancer surgery, and other cancer management services [8].

103

104 Secondary prevention reduces cervical cancer incidence and mortality by identifying and 105 treating women with pre-cancerous lesions. The World Health Organisation (WHO) 106 recommends HPV DNA testing as the primary screening test for cervical cancer, but this technology is not yet available or accessible in many countries. Cytology-based (or pap smear) 107 108 screening has been successful when implemented as part of national programmes with high 109 coverage and in settings where resources exist for patient follow-up, additional diagnostic 110 tests (colposcopy and pathology), and disease management [9]. In low-resource settings, the "see-and-treat" approach, which includes naked eye or digitally enhanced visual inspection 111 with acetic acid (VIA) to detect pre-cancerous lesions and the use of cryotherapy (liquid 112 nitrous oxide ablation) to freeze and destroy pre-cancerous tissue, has been successfully 113 114 implemented. However, the quality of VIA depends heavily on provider competence and the 115 test's sensitivity, which is variable [10–12].

116

# 117 Cervical Cancer in Eswatini

Eswatini faces a high dual burden of HIV and cervical cancer. The country's HIV prevalence of 25.9% among adults is one of the highest in the world [13], and Eswatini has the highest agestandardised cervical cancer incidence rate of 84.5 per 100,000. Only 17.6% of the country's estimated 336,037 women aged 15 – 64 years have been screened at least once for cervical cancer [14] <sup>(16)</sup>. Coverage is only slightly better for women living with HIV: estimates suggest that only 20.3% of this population has been screened [15].

124

Given the high dual burden of HIV and cervical cancer in the country, the Eswatini Ministry of 125 Health has developed several policies. In particular, the National Cancer Prevention and 126 127 Control Strategy of 2019 has set clear targets to increase the percentage of health facilities providing screening, early detection, and linkage to treatment for all cancers to 60% by 2022. 128 129 However, only 43% of health facilities have achieved this goal. Current guidelines recommend 130 screening as soon as one is sexually active for HIV-positive women, while HIV-negative women or those with unknown status can start screening from  $\geq$ 25 years. The recommended 131 frequency of cervical cancer screening is also based on HIV status and HPV infection status of 132 patients (if known). Women living with HIV are screened annually, while it is every two years 133 134 for HIV-negative women and extended to three years for those who are HIV and HPVnegative. All screening services are free in public hospitals. HPV DNA testing is not yet 135 available in the country. Fidelity to these guidelines is not monitored routinely, and when 136 done, records for non-HIV women may not be up to date. In this study, we describe the 137 cervical cancer screening outcomes, prevalence and predictors of a positive cervical screen 138 139 among HIV-positive women accessing services at selected health facilities in two regions of 140 Eswatini.

141 Methods

# 142 Study design and setting

This was a retrospective cohort study among HIV-positive women receiving HIV care at select 143 health facilities in the Lubombo and Manzini regions of Eswatini under the United States 144 Government funded Support Eswatini Achieve Sustained HIV Epidemic Control (SEASEC) 145 project. The SEASEC project is a comprehensive HIV care and treatment program 146 implemented by the Eswatini Ministry of Health (MOH) and supported by Georgetown 147 148 University. SEASEC supports the provision of cervical cancer screening and treatment of pre-149 cancerous lesions for all women living with HIV. As part of the program, healthcare workers have been trained to offer VIA, cryotherapy, and Loop Electrosurgical Excision Procedure 150 (LEEP) services. Screening supplies and equipment have also been procured and installed at 151 all seventy-five health facilities providing cervical cancer screening services in Lubombo and 152 Manzini. Additional interventions include support for quality improvement and collection and 153 154 use of service delivery data.

155 Health facilities in the Lubombo and Manzini regions are described in Table 1. Lubombo region has fifty-four health care facilities, including two hospitals (with in-patient services), one rural 156 health centre, one public health unit (equivalent to a multi-department health centre), and 157 forty-two primary health clinics. Manzini region has one hundred and twenty-three health 158 159 facilities, including four hospitals (with in-patient services), two public health units (equivalent 160 to health centres), and one hundred and seventeen primary health clinics. The SEASEC 161 Program supports eighty-six public, private or faith-based health facilities across both regions (Table 1). 162

163 164

165

166

167 Table 1: Health facilities in Manzini and Lubombo regions (Obtained from Manzini and Lubombo 168

|                          | Mai   | Manzini Region |                               | Lub              | ombo Re | gion                             |  |
|--------------------------|---|----------------|-------------------------------|------------------|---------|----------------------------------|--|
| Health Facility<br>Type  | TotalSEASECHealthSupportedFacilitiesTotalCervical |                | Total<br>Health<br>Facilities | s Total Cervical |         | Description of health facilities |  |
| Government               | 41  | 26             | services<br>26                | 30               | 25      | services<br>22                   | -No fees for all services<br>-Receives PEPFAR* support for HIV/TB<br>services<br>-Receives HIV/TB supplies from MOH  |
| Faith-based              | 19  | 13             | 7                             | 9                | 9       | 9                                | -Owned by a faith-based entity<br>-Low user fees<br>-Free HIV/TB services<br>-Receives government support<br>-Receives PEPFAR support for HIV/TB<br>services<br>-Receives HIV/TB supplies from MOH |
| NGO                      | 11  | 5              | 5                             | 2                | 2       | 1                                | -Owned by an NGO<br>-No user fees<br>-Mainly HIV/TB services<br>-Receives PEPFAR support for HIV/TB<br>services<br>-Receives HIV/TB supplies from MOH  |
| Industrial/Work<br>place | 0   | 0              | 0                             | 7                | 7       | 5                                | -Owned by the company<br>-No user fees for employees<br>-Non-employees pay user fees<br>-Receives PEPFAR support for HIV/TB<br>services<br>-Receives HIV/TB supplies from MOH                      |
| Private                  | 52  | 0              | 0                             | 6                | 0       | 0                                | -Owned by private entities<br>-Services vary (general medical to<br>specialised)<br>-Fees for all services   |
| Total                    | 123   | 44             | 38                            | 54               | 42      | 37                               |  |

Regional Health Management Team Quarterly Report. 02 2023)

169 \*United States Presidents Emergency Plan for AIDS Relief

170

The locations of these 75 health facilities that implement the SEASEC Program-supported 171 cervical screening activities are shown in Figure 1. 172

173

174

175

*Figure 1: Distribution of health facilities providing cervical cancer services in the Lubombo and* 176

177 Manzini region supported by the SEASEC Program (Generated using SEASEC Program data)

- 178
- 179 Study participants, sample size and sampling

We generated data for the study from patient attendance records from October 2020 to June 180

181 2023. The data are collected using standardised service registers provided by the Eswatini

- Ministry of Health (MOH) to all public health facilities. Our study participants were HIV-182
- positive women screened for cervical cancer from October 2020 to June 2023 at any of the 183

75 health facilities described above. Data from the two regions indicate that, as of June 2023,
a total of 69,529 women aged 15 years or older were living with HIV, and approximately
19,616 of these had received at least one cervical cancer screening [15]. Based on these data,
a minimum of 95% of women living with HIV who have received a cervical screen (18,635) will
be included in this analysis.

189

190 Data sources and study variables

Data were extracted from the National Electronic Medical Record: Client Management 191 Information System (CMIS) on the 2<sup>nd</sup> of August 2023. The required variables were filtered 192 and extracted per the study objectives. The variables describe the patient's sociodemographic 193 194 and clinical information (Table 2). Age was grouped into eight categories using 5-year age 195 bands from 15 to 50 years, while parity was categorised into 0, 1, 2 - 3, 4 - 5, and  $\geq 6$ . Marital status was grouped into two classes: married/living with a partner or single. The patient's last 196 viral load was categorised into three groups – undetectable (<50), suppressed (50<1000), and 197 unsuppressed (>1000). The timing of the cervical screening was divided into three groups – 198 first-time screening, post-treatment follow-up screening, and rescreening per the national 199 200 guideline. The VIA screening outcome was categorised into negative, positive, and suspicious. 201 The outcome variable for this study is the prevalence of a positive VIA screen, defined as the proportion of women with a positive VIA screen. 202

203

204 Statistical analysis

Data was extracted in .xls format and imported into Stata 17 (College Station, TX) for cleaning and analysis. Descriptive analysis summarised underlying trends and seasonal patterns. Key patient characteristics are presented in Table 2, disaggregated by the cervical screening outcome. Casewise analysis was used since all the patients had the outcome of interest. The

209 prevalence of positive VIA screens was presented overall and disaggregated by other patients'
210 sociodemographic and clinical information.

A new binary dependent variable – presence or absence of cervical lesion - was generated to determine the predictors of a positive cervical screen. A logistic regression model was fitted using the dependent variable and the different sociodemographic and clinical variables as predictors. A univariate model was initially built using each of the independent variables, and a stepwise forward and backward elimination process was used to select variables for inclusion in the final multivariate model at p=0.20. The final predictors were determined from the multivariate model at p<0.05.

# 218 Ethical review and approval

This study is covered under the protocol approved by the Eswatini Health and Human 219 220 Research Review Board (EHHRRB 116/2022) for Georgetown University to analyse program 221 data for dissemination. Additional approval has been obtained from the Georgetown University Institutional Review Board (GU - IRB) (STUDY 00006034) and the United States 222 223 Centers for Disease Control (CDC) (Accession #: CGH-ESW-9/14/23-15af6). Anonymised data were used to ensure confidentiality and the EHHRRB also approved an application for a waiver 224 of written informed consent from participants since the data is from routine care extracted 225 from the electronic medical records. 226

# 227 Results

228 Sociodemographic and screening outcome characteristics of study participants

Table 2 presents the descriptive characteristics of all HIV-positive patients included in the study and disaggregated by screening outcomes (negative, positive, and suspicious cervical screens). Overall, 23,657 patients accessed cervical screening services. Six hundred and three (2.6%) had a positive screen, and 60.8% (n=14, 397) were from the Manzini region. The mean age was 33.3 years (SD 7.0). Analysis by 5-year categories showed that screening increased

| 234 | gradually from 1.2% (n= 295) in the 15 – 19 age group to 25% (n=5949) in the 30 – 34 age      |
|-----|---|
| 235 | group and was consistent for both positive and negative participants. Most patients (67.3%,   |
| 236 | n=15,798) were rescreened, while 32.6% (n=7,714) were screened for the first time. About      |
| 237 | 69% (n=10, 451) were single, and more than half of the patients (55.9%, n=9,373) had a parity |
| 238 | of 0. This was similar across the three outcome groups. The majority (96.4%, n=22,770) of the |
| 239 | patients were on a dolutegravir-based ART regimen; the median duration of ART was 6.0 years   |
| 240 | (IQR 4.0, 9.0), and 95% overall had a suppressed and undetectable viral load. This is similar |
| 241 | for those who screened positive (94%, n=566).   |

242

# 243 Table 2: Descriptive characteristics of participants

| Patient Characteristics | Negative<br>(N = 22957) | Positive<br>(N = 603) | Suspicious<br>(N = 97) | Total<br>(N = 23657) |
|-------------------------|-------------------------|-----------------------|------------------------|----------------------|
| Region                  |                         |                       |                        |                      |
| Lubombo                 | 8976 (39.1%)            | 256 (42.5%)           | 39 (40.2%)             | 9297 (39.2%)         |
| Manzini                 | 13981 (60.9%)           | 347 (57.5%)           | 58 (59.8%)             | 14397 (60.8%)        |
| Age (years)             |                         |                       |                        |                      |
| 15-19                   | 284 (1.2%)              | 11 (1.8%)             | 0 (0.0%)               | 295 (1.2%)           |
| 20-24                   | 2123 (9.2%)             | 54 (9.0%)             | 2 (2.1%)               | 2194 (9.3%)          |
| 25-29                   | 4972 (21.7%)            | 108 (17.9%)           | 14 (14.4%)             | 5098 (21.5%)         |
| 30-34                   | 5776 (25.2%)            | 147 (24.4%)           | 24 (24.7%)             | 5949 (25.1%)         |
| 35-39                   | 5268 (22.9%)            | 155 (25.7%)           | 24 (24.7%)             | 5448 (23.0%)         |
| 40-44                   | 3138 (13.7%)            | 97 (16.1%)            | 18 (18.6%)             | 3268 (13.8%)         |
| 45-49                   | 1215 (5.3%)             | 27 (4.5%)             | 14 (14.4%)             | 1256 (5.3%)          |
| ≥50                     | 181 (0.8%)              | 4 (0.7%)              | 1 (1.0%)               | 186 (0.8%)           |
| Mean (SD)               | 33.29 (7.06)            | 33.53 (7.06)          | 36.47 (6.78)           | 33.31 (7.06)         |
| Parity                  |                         |                       |                        |                      |
| 0                       | 9078 (55.9%)            | 238 (57.2%)           | 33 (51.6%)             | 9373 (55.9%)         |
| 1                       | 2295 (14.1%)            | 61 (14.7%)            | 14 (21.9%)             | 2377 (14.2%)         |
| 2-3                     | 3687 (22.7%)            | 89 (21.4%)            | 12 (18.8%)             | 3789 (22.6%)         |
| 4-5                     | 1010 (6.2%)             | 22 (5.3%)             | 1 (1.6%)               | 1038 (6.2%)          |
| ≥6                      | 179 (1.1%)              | 6 (1.4%)              | 4 (6.3%)               | 189 (1.1%)           |
| Median (Q1, Q3)         | 0.0 (0.0, 2.0)          | 0.0 (0.0, 2.0)        | 0.0 (0.0, 2.0)         | 0.0 (0.0, 2.0)       |
| Duration on ART (Years) |                         |                       |                        |                      |
| Median (Q1, Q3)         | 6.0 (4.0, 8.0)          | 6.0 (3.0, 9.0)        | 7.0 (4.0, 8.0)         | 6.0 (4.0, 9.0)       |
| Facility Type           |                         |                       |                        |                      |
| Government              | 12666 (55.2%)           | 260 (43.1%)           | 49 (50.5%)             | 13003 (54.9%)        |
| Faith-based             | 6760 (29.4%)            | 180 (29.9%)           | 32 (33.0%)             | 6981 (29.5%)         |
| NGO                     | 3420 (14.9%)            | 157 (26.0%)           | 11 (11.3%)             | 3588 (15.1%)         |
| Industrial/Workplace    | 111 (0.5%)              | 6 (1.0%)              | 5 (5.2%)               | 122 (0.5%)           |
| Cervical Screening Type |                         |                       |                        |                      |
| First Time Screening    | 7427 (32.4%)            | 244 (42.0%)           | 29 (30.9%)             | 7714 (32.6%)         |
| No Outcome              | 10 (0.0%)               | 22 (3.8%)             | 2 (2.1%)               | 34 (0.1%)            |
|                         |                         |                       |                        |                      |

|  | It is made available under | а | CC-BY 4 | I.0 Internationa | l license . |
|--|----------------------------|---|---------|------------------|-------------|
|--|----------------------------|---|---------|------------------|-------------|

| Post Tx FU                  | 70 (0.3%)     | 34 (5.9%)   | 1 (1.1%)   | 105 (0.4%)    |
|-----------------------------|---------------|-------------|------------|---------------|
| Rescreening                 | 15432 (67.3%) | 281 (48.4%) | 62 (66.0%) | 15798 (66.8%) |
| Marital status              |               |             |            |               |
| Married/living with partner | 4455 (30.5%)  | 131 (34.8%) | 30 (56.6%) | 4634 (30.7%)  |
| Single                      | 10164 (69.5%) | 245 (65.2%) | 23 (43.4%) | 10451 (69.3%) |
| Last VL Outcome (cells/ml)  |               |             |            |               |
| No VL Result                | 657 (2.9%)    | 12 (2.0%)   | 2 (2.1%)   | 671 (2.8%)    |
| Suppressed (50<1000)        | 2389 (10.4%)  | 97 (16.1%)  | 8 (8.2%)   | 2494 (10.5%)  |
| Unsuppressed (≥1000)        | 406 (1.8%)    | 25 (4.1%)   | 3 (3.1%)   | 434 (1.8%)    |
| Undetectable (<50)          | 19505 (85.0%) | 469 (77.8%) | 84 (86.6%) | 20095 (84.8%) |
|                             |               |             |            |               |

244

# 245 Prevalence of positive VIA screen

The overall prevalence of a positive cervical screen was 2.6% (95% CI: 2.2%, 3.0%): 2.8% (95% 246 CI: 2.2%, 3.5%) in Lubombo and 2.4% (95% CI: 2.0%, 2.9%) in Manzini (p=0.096). The 247 prevalence was further analysed by age group, ART duration, parity, and cervical screening 248 249 type (Table 3). The prevalence ranged from 2.1% (95% CI: 1.5%, 3.0%) in the 25 – 29 years age 250 group to 3.7% (95% CI: 1.3%, 9.9%) in the 15 - 19 years age group, and it was statistically 251 higher in the 40 - 44 years age group in Lubombo (4.2%; 95% CI: 2.5%, 6.8%) compared to those in Manzini (2.1%; 95% CI: 1.4%, 3.1%) (p=0.001). Patients with parity ≥6 had an overall 252 higher prevalence of 3.2% (95% CI: 0.5%, 19.5%), while those with parity=0 had a higher 253 254 prevalence in Lubombo compared to Manzini (p=0.004). Prevalence was higher in patients 255 receiving post-treatment follow-up screening at 32.7% (95% CI: 20%, 49%) and lowest in rescreening patients. 256

257

258

- 259
- 260
- 261

262

263

| 204 | Patient Characteristics      | % Prevalence (95% Confidence Interval) |                              |                    |        |  |
|-----|------------------------------|--|------------------------------|--------------------|--------|--|
|     |                              | Lubombo                                | Manzini                      | Overall            |        |  |
|     | Region                       | 2.8% [2.2,3.5]                         | 2.4% [2.0,2.9]               | 2.6% [2.2,3.0]     |        |  |
|     | Facility Type                |  |                              |                    |        |  |
|     | Government                   | 2.1% [1.6,2.8]                         | 1.9% [1.4,2.6]               | 2.0% [1.6,2.5]     | 0.440  |  |
|     | Mission                      | 4.7% [3.2,7.0]                         | 1.6% [1.0,2.6]               | 2.6% [1.9,3.5]     | <0.001 |  |
|     | NGO                          | 0.0%                                   | 4.4% [3.5,5.6]               | 4.4% [3.5,5.6]     | -      |  |
|     | Industrial/Workplace         | 5.1% [2.3,10.9]                        | 0.0%                         | 5.1% [2.3,10.9]    | -      |  |
|     | Age group (years)            |  |                              |                    |        |  |
|     | 15-19                        | 5.9% [1.4,21.7]                        | 2.3% [0.7,7.4]               | 3.7% [1.3,9.9]     | 0.108  |  |
|     | 20-24                        | 2.4% [1.1,5.2]                         | 2.6% [1.5,4.4]               | 2.5% [1.6,3.9]     | 0.789  |  |
|     | 25-29                        | 2.4% [1.3,4.2]                         | 2.0% [1.2,3.2]               | 2.1% [1.5,3.0]     | 0.389  |  |
|     | 30-34                        | 2.6% [1.5,4.4]                         | 2.4% [1.6,3.6]               | 2.5% [1.8,3.4]     | 0.632  |  |
|     | 35-39                        | 2.4% [1.4,4.1]                         | 3.1% [2.3,4.3]               | 2.9% [2.2,3.8]     | 0.136  |  |
|     | 40-44                        | 4.2% [2.5,6.8]                         | 2.1% [1.4,3.1]               | 3.0% [2.1,4.2]     | 0.001  |  |
|     | 45-49                        | 2.1% [1.0,4.7]                         | 2.2% [1.3,3.6]               | 2.2% [1.4,3.4]     | 0.932  |  |
|     | ≥50                          | 4.9% [1.8,12.3]                        | 0.0%                         | 2.2% [0.8,5.6]     | -      |  |
|     | ART duration                 |  |                              |                    |        |  |
|     | <5 years                     | 3.2% [2.2,4.8]                         | 2.8% [2.2,3.7]               | 3% [2.4,3.7]       | 0.332  |  |
|     | 5-9years                     | 2.5% [1.7,3.6]                         | 2.3% [1.7,3.1]               | 2.4% [1.9,3.0]     | 0.425  |  |
|     | >=10years                    | 2.8% [1.8,4.4]                         | 2.0% [1.4,2.8]               | 2.3% [1.7,3.2]     | 0.070  |  |
|     | Parity                       |  |                              |                    |        |  |
|     | 0                            | 3.2% [2.2,4.6]                         | 2.2% [1.6,3.0]               | 2.6% [2.0,3.2]     | 0.004  |  |
|     | 1                            | 3.1% [1.6,5.9]                         | 2.2% [1.1,4.4]               | 2.6% [1.6,4.1]     | 0.184  |  |
|     | 2-3                          | 2.7% [1.4,5.0]                         | 2.1% [1.2,3.6]               | 2.4% [1.6,3.5]     | 0.272  |  |
|     | 4-5                          | 2.0% [0.8,5.0]                         | 2.3% [0.7,7.0]               | 2.1% [1.0,4.4]     | 0.768  |  |
|     | ≥6                           | 4.7% [0.7,26.4]                        | 0.0%                         | 3.2% [0.5,19.5]    | 0.097  |  |
|     | Frequency of screening       |  |                              |                    |        |  |
|     | First Time Screening         | 4.0% [2.4,6.5]                         | 2.9% [2.2,3.9]               | 3.2% [2.5,4.1]     | 0.068  |  |
|     | Post Treatment Follow-<br>Up | 37.1% [16.5,64]                        | 30.4%<br>[15.6 <i>,</i> 50.9 | 32.7%<br>[20,49.0] | 0.491  |  |
|     | Rescreening                  | 1.9% [1.4,2.6]                         | 1.7% [1.3,2.1]               | 1.8% [1.5,2.2]     | 0.235  |  |
| 265 | *Compares Lubombo and I      | Manzini                                |                              |                    |        |  |

### 264 Table 3: Prevalence of a positive cervical screen

266

Follow-up VIA screening 267

Two hundred and twenty-three of 603 patients with a positive first VIA result had follow-up 268 VIA results. Of the 223, 125 (56%) had a negative result, 89 (40%) had a positive result, and 9 269 270 (4%) had a suspicious result. Only 21 of 97 patients with a suspicious result had a follow-up 271 VIA result: 5 (23.8%) were negative, 3 (14.3%) were positive, and 13 (61.9%) remained suspicious. Of 22,957 patients with a negative VIA result, follow-up screening data was 272

- available for 8403 patients: 8,288 (98.6%) remained negative, 50 (0.6%) were positive, and 13
- 274 (0.15%) had a suspicious result.
- 275 Predictors of a positive cervical screen

The predictors of a positive cervical screen are presented in Table 4. In the univariate analysis, screenings at mission-owned, NGO-owned, and industrial/workplace-owned health facilities were significant positive predictors of a positive cervical cancer screening result compared to screening at a government-owned health facility. Being on ART for 5 – 9 years and  $\geq$ 10 years compared to being on ART for less than 5 years and having an undetectable viral load compared to an unsuppressed viral load were significant negative predictors of a positive cervical screen.

283 In the multivariate analysis, significant negative predictors of a positive cervical screen were residing in the Manzini region (OR 0.55; 95% CI: 0.45, 0.67; p<0.001) compared to Lubombo; 284 285 being on ART for 5 – 9 years duration (OR 0.76; 95% CI: 0.62, 0.92; p=0.004) and  $\geq$ 10 years (OR 0.66; 95% CI: 0.50, 0.85; p=0.002) compared to less than 5 years; and having an 286 undetectable viral load result (OR 0.39; 95% CI: 0.26, 0.59; p<0.001) compared to an 287 unsuppressed viral load. Being screened at mission-owned (OR 1.40; 95% CI: 1.15, 1.72; 288 p=0.001), NGO-owned (OR 3.08; 95% CI: 2.41, 3.95; p<0.001) and industrial/workplace-289 owned (OR 2.37; 95% CI: 1.02, 5.49; p=0.044) compared to government-owned health 290 291 facilities, and being within the 35 – 44 age group (OR 1.26; 95% CI: 1.04, 1.53; p=0.017) compared to 25-34 years age group, were significant positive predictors of a positive cervical 292 293 screen.

294

295

296

### 297 Table 4: Univariate and Multivariate Predictors of Abnormal Cervical Screen

|                         | Univari           | ate      | Multivariate      |          |  |
|-------------------------|-------------------|----------|-------------------|----------|--|
| Predictor               | OR (95% CI)       | P-Value* | OR (95% CI)       | P-Value* |  |
| Region                  |                   |          |                   |          |  |
| Lubombo                 | 1                 |          | 1                 |          |  |
| Manzini                 | 0.87 (0.74, 1.02) | 0.096    | 0.55 (0.45, 0.67) | <0.001   |  |
| Health Facility Type    |                   |          |                   |          |  |
| Government              | 1                 |          | 1                 |          |  |
| Mission                 | 1.30 (1.07, 1.57) | 0.008    | 1.40 (1.15, 1.72) | 0.001    |  |
| NGO                     | 2.24 (1.83, 2.74) | <0.001   | 3.08 (2.41, 3.95) | <0.001   |  |
| Industrial/Workplace    | 2.63 (1.15, 6.04) | 0.022    | 2.37 (1.02, 5.49) | 0.044    |  |
| Age (years)             |                   |          |                   |          |  |
| 25-34                   | 1                 |          | 1                 |          |  |
| 15-24                   | 0.88 (0.67, 1.16) | 0.358    | 1.04 (0.78, 1.39) | 0.777    |  |
| 35-44                   | 1.11 (0.84, 1.46) | 0.459    | 1.26 (1.04, 1.53) | 0.017    |  |
| 45+                     | 0.82 (0.53, 1.27) | 0.376    | 0.83 (0.55, 1.24) | 0.361    |  |
| Duration on ART (Years) |                   |          |                   |          |  |
| <5 years                | 1                 |          | 1                 |          |  |
| 5 – 9 years             | 0.79 (0.66, 0.94) | 0.009    | 0.75 (0.62, 0.92) | 0.004    |  |
| => 10 years             | 0.78 (0.62, 0.99) | 0.038    | 0.66 (0.50, 0.85) | 0.002    |  |
| Marital status          |                   |          |                   |          |  |
| Married/Partner         | 1                 |          |                   |          |  |
| Single                  | 0.82 (0.66, 1.02) | 0.070    |                   |          |  |
| Parity                  |                   |          |                   |          |  |
| 0                       | 1                 |          |                   |          |  |
| 1                       | 1.01 (0.76, 1.35) | 0.925    |                   |          |  |
| 2-3                     | 0.92 (0.72, 1.18) | 0.511    |                   |          |  |
| 4-5                     | 0.83 (0.53, 1.29) | 0.411    |                   |          |  |
| ≥6                      | 1.28 (0.56, 2.91) | 0.559    |                   |          |  |
| Last Viral Load Outcome |                   |          |                   |          |  |
| Unsuppressed (≥1000)    | 1                 |          | 1                 |          |  |
| Suppressed (50<1000)    | 0.66 (0.42, 1.04) | 0.071    | 0.66 (0.42, 1.04) | 0.071    |  |
| Undetectable (<50)      | 0.39 (0.26, 0.59) | <0.001   | 0.39 (0.26, 0.59) | <0.001   |  |
|                         |                   |          |                   |          |  |

298

299

### Discussion 300

We aimed to describe the cervical cancer screening outcomes, prevalence, and predictors of 301 302 a positive cervical screen in the women living with HIV who accessed services at select health facilities in the Lubombo and Manzini regions of Eswatini. Our study findings suggest that the 303 percent positivity for cervical cancer screening tests among WLHIV is 2.6%, lower than 304 305 reported in the literature from studies in similar settings, regardless of the type of screening

test used. A previous cross-sectional study in Eswatini found that the presence of cervical 306 307 lesions was higher in HIV-positive (22.9%) than HIV-negative women (5.7%; p < 0.0001) [16], and another study in Eswatini found a VIA positivity rate of 9% in the general population [17]. 308 Elsewhere in Africa, a large cohort study of women in Zambia who were screened with VIA 309 and digital cervicography (VIAC) had a positivity rate of 10.4% for the general population, with 310 311 WLHIV having a much higher rate of 53.3% [18]. In Nigeria, a study using program data found 312 a VIA positivity rate of 7.1% [19]. In another study assessing HPV testing for WLHIV, 46.5% in 313 Burkina Faso and 43.8% in South Africa had a positive HPV test [20]. In a hospital-based study conducted in Ethiopia, the prevalence of a pre-cancerous cervical lesion was 9.3% among 314 315 WLHIV [21].

This finding of a lower-than-expected positivity rate in Eswatini compared to the studies cited 316 above points to the need for further research into the screening offered in health facilities. 317 318 Given the literature around VIA screening, the learning curve to implement this screening test 319 is high, and the results during initial phases often reflect lower positivity rates. Future 320 research can help determine whether the lower-than-expected positivity rate is due to a need for strengthening screening services or is an accurate reflection of rates among this 321 population. Given the move towards the recent WHO guidelines in Eswatini, HPV-DNA is being 322 recommended for use as the primary screening test. Eswatini has yet to fully roll out this 323 324 testing modality; hence, ensuring the quality of the existing VIA screening test is essential 325 even as the government works to expand access to HPV DNA testing.

Another observation from our study is that the prevalence of a positive screening result was associated with accessing services at faith-based, NGO-owned and industrial/workplaceowned health facilities. This observation could be due to several reasons. First, personnel at

329 these types of health facilities who provide cervical screening services are assigned to VIA 330 screening as part of their ongoing, long-term responsibilities, which enables them to acquire skills and expertise over time. In comparison, health personnel at government-owned health 331 facilities are not stationed at the VIA unit; they rotate from their role to another unit or health 332 facility every twelve months. This rotation limits the skill and expertise in cervical screening. 333 334 Secondly, the facilities with more positive screens have access to better screening equipment 335 with better utilisation than government-owned facilities. Third, these health facilities enforce 336 higher quality standards on VIA screening with strict adherence to the screening standard operating procedure (SOP) and supervision than government-owned health facilities. Fourth, 337 338 they provide supplemental training for their staff in addition to the required minimum 339 training for health personnel providing VIA and cervical cancer services.

340 A positive screening result in our study was also associated with being aged between 35 – 44 vears, compared to older and younger age groups. This finding is consistent with findings from 341 several sub-Saharan African countries that the burden of cervical cancer attributable to HIV 342 343 is highest among younger women aged less than 45 [22]. Longer duration on ART and an undetectable viral load were protective in our analysis, which is consistent with other studies 344 and could be attributed to the increased immune function, which reduces the incidence and 345 346 progression of squamous intraepithelial lesion (SIL) and cervical intraepithelial neoplasia (CIN) and, ultimately, the incidence of invasive cervical cancer when patients are stable on ART 347 348 [23]). Other predictors of positive screening results vary in the literature. Studies have found that predictors of pre-cancerous cervical lesions or positive cervical cancer screening results 349 among WLHIV include increasing parity [24], a history of multiple sexual partners, and sexually 350

transmitted infections [25]. In the general population, predictors of VIA positivity include
having multiple sexual partners, having an early sexual debut, and being older [17,26].

353 Our study had several strengths, notably the large sample size of nearly 24,000 women. 354 Regionwide coverage of public, faith-based, NGO-owned and industrial/workplace-owned health facilities limits any possible effects of clinic-based selection bias. There was a high rate 355 of data completion on the results of screening tests, with very few participants lost to follow-356 357 up or with missing data. Given our study's large number of health facilities, the findings highly represent the two regions. On the contrary, the study conclusions were limited in 358 359 generalizability, as the SEASEC project supported all sites included in this study. These findings may not apply to settings not supported by the SEASEC project. This is also important for 360 361 planning future research to outline the role of the support partners, the characteristics of the settings, and the support received. Another limitation of our study is excluding private health 362 363 facilities, which are not SEASEC-supported. A challenge with private health facilities includes difficulty accessing their data, uncertainty about the type of services they offer, and whether 364 365 they adhere to standard MOH guidelines.

Eswatini has yet to achieve its target of scaling up cervical cancer services. Scaling up cervical cancer services to more health facilities with targeted, demand-driven activities and patient education will increase cervical screening coverage in Eswatini. More positive screens can be identified, and women can be offered treatment with a higher coverage.

370 Government-owned health facilities should adopt practices to increase accountability for 371 cervical screening services with measures to track adherence to cervical screening standards, 372 standard operating procedures, supportive supervision, and mentoring for staff who require 373 additional skills.

Early HIV case finding and scaling up ART uptake for women in different at-risk populations can limit non-suppression and lower the risk of a positive cervical screen. Moreover, scaling up HIV services overall will increase cervical screening opportunities.

Although Eswatini has just commenced HPV vaccinations for eligible females, the implementation has not been country-wide due to the limited availability of the vaccine. This should be scaled up to all regions with provisions to make it accessible for eligible residents of remote, hard-to-reach locations. The general public should receive adequate information on the vaccine's benefits, including details of where and how they can access additional information on the HPV vaccines.

Finally, additional studies are required to identify other possible causes of the lower-thanexpected VIA positivity rate in selected facilities with strategies to address the identified gaps. Ongoing screening with VIA should be standardised across all health facilities, focusing on improving the health system structures required for a comprehensive screening program. Efforts to expand access to HPV DNA testing should be fast-tracked, prioritising screening for vulnerable women, including WLHIV.

389

390

391

392

393

394

395

396

### **Acknowledgements** 397

We thank all the clients and healthcare workers, without which this study would not have 398 been possible. We also thank the monitoring and evaluation team at Georgetown University 399 400 Eswatini, who diligently collected the data reported in the article.

### Funding 401

The Support Eswatini Achieve and Sustain HIV Epidemic Control (SEASEC) Program is 402 supported by the U.S President's Emergency Plan for AIDS Relief through the Centers for 403 404 Disease Control and Prevention (Co-operative Agreement No.:NU2GGH002294), 405 implemented by Georgetown University in collaboration with the Government of the Kingdom of Eswatini. The funders had no role in the conceptualization of the study, study 406 design, data collection and analysis, decision to publish and preparation of the manuscript. 407

408

### **Contributions** 409

RM, VW, SO and SH conceptualised the study. NM, TM, RC, SG, PM, HB, and DG participated 410 in data capturing and verification at health facilities supervised by VW and AM. VW, AM and 411 TM conducted the data analysis. RM, VW, and SG wrote the first draft of the manuscript. SK, 412 413 ADM, PA, PB, CL, XD, DB, and SO contributed substantially to manuscript revisions. All authors contributed to interpreting the results and reviewing different drafts of the manuscript. All 414

authors read and approved the final draft. 415

### Declarations 416

### 417 Data availability

418 The data presented in this research are available upon a reasonable request to the 419 corresponding author.

- 420 **Competing Interests**
- 421 The authors declare no competing interests.

### 422 Ethical review and approval

This study is covered under the protocol approved by the Eswatini Health and Human 423 Research Review Board (EHHRRB 116/2022) for Georgetown University to analyse program 424 425 data for dissemination. The EHHRRB also approved a waiver of informed consent by patients. 426 Additional approval has been obtained from the Georgetown University Institutional Review 427 Board (GU - IRB) (STUDY 00006034) and the United States Centers for Disease Control (CDC) (Accession #: CGH-ESW-9/14/23-15af6). Anonymised data were used to ensure 428 confidentiality and the EHHRRB also approved an application for a waiver of written informed 429 consent from participants since the data is from routine care extracted from the electronic 430 medical records. 431


- 432
- 433
- 434

# 435 **REFERENCES**

- World Health Organisation. WHO Cervical Cancer Elimination Initiative: from call to action to global movement [Internet]. Geneva: WHO; 2023 May [cited 2023 1 Nov].
   Available from: https://www.who.int/publications/m/item/who-cervical-cancerelimination-initiative--from-call-to-action-to-global-movement
- Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023 Feb;11(2):e197–206.
- Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, et al. Safety and
  immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like
  particle vaccine. J Natl Cancer Inst. 2001 Feb 21;93(4):284–92.
- 447 4. Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, et al. Estimates of
  448 the global burden of cervical cancer associated with HIV. Lancet Glob Health. 2021
  449 Feb;9(2):e161–9.
- 450 5. Massad LS, Hessol NA, Darragh TM, Minkoff H, Colie C, Wright RL, et al. Cervical cancer
  451 incidence after up to 20 years of observation among women with HIV. Int J Cancer. 2017
  452 15 Oct;141(8):1561–5.
- 453 6. World Health Organisation. Consolidated guidelines on the use of anti-retroviral drugs
  454 for treating and preventing HIV infection: recommendations for a public health
  455 approach, 2nd ed [Internet]. Geneva: WHO; 2016 Jun [cited 2023 1 Nov]. Available from:
  456 https://www.who.int/publications-detail-redirect/9789241549684
- 457 7. Castle PE, Einstein MH, Sahasrabuddhe VV. Cervical cancer prevention and control in
  458 women living with human immunodeficiency virus. CA Cancer J Clin. 2021
  459 Nov;71(6):505–26.
- 8. World Health Organisation. Global strategy to accelerate the elimination of cervical cancer as a public health problem [Internet]. Geneva: WHO; 2020 Nov [cited 2023 1
  Nov]. Available from: https://www.who.int/publications-detail-redirect/9789240014107
- 464 9. Denny L. Cytological screening for cervical cancer prevention. Best Pract Res Clin Obstet
   465 Gynaecol. 2012 Apr;26(2):189–96.
- Sami J, Lemoupa Makajio S, Jeannot E, Kenfack B, Viñals R, Vassilakos P, et al.
  Smartphone-Based Visual Inspection with Acetic Acid: An Innovative Tool to Improve
  Cervical Cancer Screening in Low-Resource Setting. Healthc Basel Switz. 2022 Feb
  18;10(2):391.
- 470 11. Cubie HA, Campbell C. Cervical cancer screening The challenges of complete pathways
  471 of care in low-income countries: Focus on Malawi. Womens Health Lond Engl.
  472 2020;16:1745506520914804.
- World Health Organisation. WHO guideline for screening and treatment of cervical precancer lesions for cervical cancer prevention, second edition [Internet]. Geneva: WHO;
  2021 Dec [cited 2023 1 Nov]. Available from: https://www.who.int/publications-detailredirect/9789240040434

- 477 13. UNAIDS. UNAIDS Country Factsheet: Eswatini 2022 [Internet]. 2023 [cited 2023 1 Nov].
  478 Available from: https://www.unaids.org/en/regionscountries/countries/swaziland
- 479 14. Eswatini Ministry of Health. National Cancer Control Program: Cervical Cancer Screening
  480 Report 2019. Mbabane, Eswatini: MOH; 2020.
- 481 15. Eswatini Ministry of Health. Support Eswatini Achieve Sustained HIV Epidemic Control
  482 (SEASEC): Data for accountability, transparency, and Impact (DATIM) April June 2023
  483 Report for Lubombo and Manzini Regions. Mbabane: MOH; 2023 Jul.
- Io. Jolly PE, Mthethwa-Hleta S, Padilla LA, Pettis J, Winston S, Akinyemiju TF, et al.
  Screening, prevalence, and risk factors for cervical lesions among HIV positive and HIV
  negative women in Swaziland. BMC Public Health. 2017 Feb 21;17(1):218.
- I7. Jolly PE, Mthethwa-Hleta S, Padilla LA, Pettis J, Winston S, Akinyemiju TF, et al.
  Screening, prevalence, and risk factors for cervical lesions among HIV positive and HIV
  negative women in Swaziland. BMC Public Health. 2017 Feb 21;17(1):218.
- Pry JM, Manasyan A, Kapambwe S, Taghavi K, Duran-Frigola M, Mwanahamuntu M, et
  al. Cervical cancer screening outcomes in Zambia, 2010-19: a cohort study. Lancet Glob
  Health. 2021 Jun;9(6):e832–40.
- 493 19. Ogunsola OO, Ajayi OA, Ojo TO, Osayi E, Wudiri K, Amoo B, et al. Cervical cancer
  494 screening and treatment for PLWHIV: experiences from an innovative program in
  495 Nigeria. Reprod Health. 2023 Aug 26;20(1):125.
- Segondy M, Kelly H, Magooa MP, Djigma F, Ngou J, Gilham C, et al. Performance of
  careHPV for detecting high-grade cervical intraepithelial neoplasia among women living
  with HIV-1 in Burkina Faso and South Africa: HARP study. Br J Cancer. 2016 9
  Aug;115(4):425–30.
- Kiros M, Mesfin Belay D, Getu S, Hailemichael W, Esmael A, Andualem H, et al.
  Prevalence and Determinants of Pre-Cancerous Cervical Lesion and Human
  Papillomavirus Among HIV-Infected and HIV-Uninfected Women in North-West
  Ethiopia: A Comparative Retrospective Cross-Sectional Study. HIVAIDS Auckl NZ.
  2021;13:719–25.
- So5 22. Ibrahim Khalil A, Mpunga T, Wei F, Baussano I, de Martel C, Bray F, et al. Age-specific
  burden of cervical cancer associated with HIV: A global analysis with a focus on subSaharan Africa. Int J Cancer. 2022 1 Mar;150(5):761–72.
- Kelly H, Weiss HA, Benavente Y, de Sanjose S, Mayaud P, ART and HPV Review Group.
  Association of anti-retroviral therapy with high-risk human papillomavirus, cervical
  intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a
  systematic review and meta-analysis. Lancet HIV. 2018 Jan;5(1):e45–58.
- 512 24. Daniel GO, Musa J, Akindigh TM, Shinku F, Shuaibu SI, Kwaghe B, et al. Prevalence and
  513 predictors of pre-cancerous cervical lesions among HIV-positive women in Jos, north514 central Nigeria. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2020
  515 Nov;151(2):253–9.
- 516 25. Kafuruki L, Rambau PF, Massinde A, Masalu N. Prevalence and predictors of Cervical
  517 Intraepithelial Neoplasia among HIV infected women at Bugando Medical Centre,
  518 Mwanza-Tanzania. Infect Agent Cancer. 2013 Nov 15;8(1):45.

- 26. Fentie AM, Tadesse TB, Gebretekle GB. Factors affecting cervical cancer screening 519 520 uptake, visual inspection with acetic acid positivity and its predictors among women 521 attending cervical cancer screening service in Addis Ababa, Ethiopia. BMC Womens 522 Health. 2020 Jul 16;20(1):147.
- 523
- 524
- 525
- 526
- 527







# Figure 1\_Distribution of health facilities